CML patients carry the t(9;22) (q34;q11) translocation [1], which is responsible for the expression of p210 BCR-ABL, a constitutively active tyrosine kinase [2]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.